[0004a] In one aspect, there is provided an injectable monotherapeutic formulation for regional adiposity reduction by local administration, wherein the single active agent is a lipophilic long-acting selective beta-2 adrenergic receptor agonist, or a salt, solvate, or polymorph thereof that is present in an amount that is less than about 20 μg and wherein the formulation consists of one or more subcutaneously acceptable inactive ingredients and a lipophilic long-acting selective beta-2 adrenergic receptor agonist, or a salt, solvate, or polymorph thereof.

[0004b] In one aspect, there is provided a method for reducing adiposity in a human patient for cosmetic purposes by local injection of a monotherapy formulation wherein the single active agent is a lipophilic long-acting selective beta-2 adrenergic receptor agonist, or a salt, solvate, or polymorph thereof that is present in an amount that is less than about 20 μg and wherein the injectable formulation consists of one or more subcutaneously acceptable inactive ingredients and a lipophilic long-acting selective beta-2 adrenergic receptor agonist, or a salt, solvate, or polymorph thereof.

[0004c] In one aspect, there is provided the use of an injectable formulation as defined herein in the manufacture of a medicament for use in reducing adiposity, inducement of lipolysis in adipose tissue or treating thyroid eye disease, wherein the formulation is to be administered subcutaneously.

[0004d] In one aspect, there is provided the use of an injectable formulation as defined herein in a cosmetic method or aesthetic treatment, wherein the formulation is administered subcutaneously; optionally wherein the use is for reducing adiposity, inducement of lipolysis in adipose tissue, treating thyroid eye disease, or aesthetic application to contour defects.